Conference Coverage

Women and ACS: Focus on typical symptoms to improve outcomes


 

FROM GOING BACK TO THE HEART OF CARDIOLOGY

‘Yentl syndrome’ persists

“Women should not need to present exactly like men to be taken seriously,” she said, describing the “Yentl syndrome,” which now has its own Wikipedia page. A cardiovascular version of this syndrome was first described 30 years ago. Based on a movie of a woman who cross dresses in order to be allowed to undertake Jewish studies, the term captures the societal failure to adapt care for women who do not present disease the same way that men do.

Overall, inadequate urgency to pursue potential symptoms of ACS in women is just another manifestation of the “bikini approach to women’s health,” according to Dr. Gulati. This describes the focus on the breast and reproductive system to the exclusion or other organs and anatomy. Dr. Gulati speculated that this might be the reason that clinicians have failed to apply ACS guidelines to women with the same rigor that they apply to men.

This is hardly a new issue. Calls for improving cardiovascular care in women have been increasing in volume for more than past 20 years, but the issue has proven persistent, according to Dr. Gulati. As an example, she noted that the same types of gaps in care and in outcome reported in a 2008 registry study had not much changed in an article published 8 years later.

The solution is not complex, according to Dr. Gulati. In the ED, guideline-directed diagnostic tests should be offered to any man or woman, including younger women, who present with chest pain, ignoring gender bias that threatens misinterpretation of patient history and symptoms. Once CVD is diagnosed as promptly in women as it is in men, guideline-directed intervention would be expected to reduce the gender gap in outcomes.

“By applying standardized protocols, it will help us to the same for women as we do for men,” Dr. Gulati said.

The meeting was sponsored by MedscapeLive. MedscapeLive and this news organization are owned by the same parent company.

Pages

Recommended Reading

Virtual AHA 2020 may influence template for postpandemic scientific sessions
MDedge Internal Medicine
Methotrexate and hydroxychloroquine split on cardiovascular outcomes in RA
MDedge Internal Medicine
Combined OCT, cardiac MRI unravels root cause in most MINOCA
MDedge Internal Medicine
SCAPIS: Simple questionnaire can identify silent atherosclerosis
MDedge Internal Medicine
Cardiac arrest in COVID-19 pandemic: ‘Survival is possible’
MDedge Internal Medicine
Colchicine a case study for what’s wrong with U.S. drug pricing
MDedge Internal Medicine
CVD deaths rose, imaging declined during pandemic
MDedge Internal Medicine
Tofacitinib for RA misses the mark in safety study
MDedge Internal Medicine
FDA alert confirms heart and cancer risks with tofacitinib (Xeljanz)
MDedge Internal Medicine
ColCORONA: More questions than answers for colchicine in COVID-19
MDedge Internal Medicine